 |
市場調查報告書
商品編碼
1983213
耳鼻喉疾病治療市場：依治療方法、藥物、器官、最終用戶和地區分類ENT Disorder Treatment Market, By Treatment Type, By Drugs, By Organ Type, By End User, By Geography |
||||||
預計到 2026 年，耳鼻喉疾病治療市場規模將達到 365.3 億美元，到 2033 年將達到 573 億美元。預計從 2026 年到 2033 年，該市場將以 6.6% 的複合年成長率成長。
| 分析範圍 | 分析詳情 | ||
|---|---|---|---|
| 基準年 | 2025 | 市場規模（2026 年） | 365.3億美元 |
| 效能數據 | 2020-2024 | 預測期 | 2026-2033 |
| 預測期（2026-2033 年）複合年成長率 | 6.60% | 預計金額（2033 年） | 573億美元 |
耳鼻喉科（ENT）是醫學的一個分支，專門治療與耳、鼻、喉相關的疾病。耳、鼻、喉疾病會嚴重影響生活品質，某些疾病，例如慢性扁桃腺炎、耳部感染疾病和嚴重鼻竇炎，可能需要手術治療，咽喉癌或喉癌也是如此。治療這些疾病需要耳鼻喉科專家的專業知識。雖然這些疾病可以透過醫療設備和藥物治療，但在嚴重的情況下，建議進行手術。在某些情況下，例如喉癌，根據耳鼻喉科專家的建議，必須進行手術介入。然而，腫瘤切除手術由腫瘤科醫師進行，術後是否進行放射治療或化療則取決於疾病的嚴重程度。
市場動態
主要企業正專注於非內部成長策略，例如透過合作和收購來加強其研發部門，並在銷售和行銷方面實現產品商業化。例如，2017年7月，Entellus Medical宣布達成最終協議，收購Spirox, Inc.，這是一家私營的耳鼻喉科醫療技術公司，主要從事可吸收鼻植入和其他醫療設備的研發、生產和銷售。
此外，2021年8月，全球醫療技術領導者Medtronic plc.）與全球耳鼻喉科（ENT）醫療技術領導者Intersect ENT達成協議。 Intersect ENT致力於革新患者照護。根據該協議，Medtronic以每股28.25美元的價格，以全現金交易方式收購了Intersect ENT的全部股份，公司估值約為11億美元。兩家公司的董事會均一致核准了該交易。Medtronic力收購Intersect ENT將擴展其用於耳鼻喉科手術的產品系列。互補的產品線和美Medtronic的努力預計將對慢性鼻竇炎（CRS）患者產生積極影響。 Intersect ENT的PROPEL®和SINUVA®鼻竇植入是經臨床驗證的解決方案，可打開鼻竇通道並輸送抗發炎類固醇以促進癒合。透過將這些產品與Medtronic的導航系統、電動手術器械和現有的組織健康相關產品相結合，該公司旨在提供更廣泛的解決方案，以支持外科醫生治療 CRS 患者。
本報告的主要特點
- 本報告指出了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
- 此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
- 本節根據以下參數介紹全球耳鼻喉疾病治療市場的主要企業概況：公司概況、產品系列、主要亮點、財務表現和策略。
- 本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
- 《全球耳鼻喉疾病治療市場》報告面向該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
- 相關人員可以透過分析全球耳鼻喉疾病治療市場中使用的各種策略矩陣來促進決策。
目錄
第1章：分析目標與假設
- 分析目的
- 先決條件
- 簡稱
第2章 市場展望
- 報告說明
- 市場定義和範圍
- 執行摘要
第3章：市場動態、監管與趨勢分析
- 市場動態
- 影響分析
- 主要亮點
- 法規環境
- 產品上市及核准
- PEST分析
- 波特五力分析
- 市場機遇
- 法規環境
- 主要進展
- 產業趨勢
第4章：全球耳鼻喉疾病治療市場：依治療方法分類（2020-2033 年）
- 醫療設備
- 藥物
第5章 全球耳鼻喉疾病治療市場：依器官分類（2020-2033 年）
- 耳朵
- 鼻子
- 喉
第6章 全球耳鼻喉疾病治療市場：以最終使用者分類（2020-2033 年）
- 醫院
- 診所
- 門診手術中心
- 居家醫療設施
- 其他
第7章 全球耳鼻喉疾病治療市場：依地區分類（2020-2033年），市場規模
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太地區
- 中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
- 非洲
- 南非
- 北非
- 中非
第8章 競爭情勢
- Sanofi
- AstraZeneca Plc
- Novartis AG
- Pfizer, Inc.
- Mylan NV
- Teva Pharmceutical Industries Ltd.
- GlaxoSmithKline Plc
- Otonomy, Inc.
- Merck &Co., Inc.
- Dr. Reddy's Laboratories Ltd.
- Allergen Plc
- Cochlear Ltd.
- Sonova Holdings AG.
- Siemens Healthineers
- Starkey Laboratories, Inc.
- William Demant Holdings, A/S
- Widex A/S
- GN Re/Sound A/S
- Sonic Innovations. Inc.
- Panasonic Corporation
- Beltone
- Rexton Inc.
- Avada Hearing Care
- Miracle-Ear., Inc.
- MED-EL GmBH
- Nuear Hearing Aids, Inc.
- AudioSync, Inc.
- Bernafon
- American Hearing Systems, Inc.
- Unitron Hearing, Inc.
- Zounds, Inc.
第9章 分析師建議
- 機會
- 分析師意見
- Coherent Opportunity Map (COM)
第10章：參考文獻與分析方法
- 參考
- 分析方法
- 關於 Coherent Market Insights
Ent Disorder Treatment Market is estimated to be valued at USD 36.53 Bn in 2026 and is expected to reach USD 57.30 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 36.53 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.60% | 2033 Value Projection: | USD 57.30 Bn |
ENT also known as otolaryngology is a stream of medical science that deals with disorders associated with ear, nose, and throat. Diseases related to ears, throat, and nose significantly affect the quality of life and could lead to surgeries in few cases such as chronic tonsillitis, ear infections, and severe sinusitis problems as well as cancers of the throat or larynx, and others. In order to treat these disorders, ENT treatment is required. These diseases can either be treated with the help of devices or drugs, however, surgeries are recommended to patients with severe cases. Surgical procedures are required in few cases such as throat cancer as recommended by otolaryngologist, however, an oncologist performs the tumor removal procedures, which is either followed by a radiation or chemotherapy, depending on the severity.
Market Dynamics
Key players are focusing on inorganic growth strategies such as agreement and acquisitions for enhancement of research department as well as commercialization of products in terms of sales and marketing. For instance, in July 2017, Entellus Medical announced a definitive agreement to acquire Spirox, Inc. a privately held ENT medical technology that develops, manufactures and markets absorbable nasal implants and other medical devices.
Moreover, in August 2021, Medtronic plc., the global leader in medical technology signed agreement with Intersect ENT, a global ear, nose, and throat (ENT) medical technology leader dedicated to transforming patient care, in which Medtronic acquired all shares of Intersect ENT for USD28.25 per share in an all-cash transaction implying an enterprise value of approximately USD1.1 billion. The boards of directors of both companies have unanimously approved the transaction. Medtronic's acquisition of Intersect ENT expands the company's portfolio of products used during ear, nose, and throat procedures. The complementary product lines and Medtronic's efforts to have a positive impact for patients who suffer from chronic rhinosinusitis (CRS). Intersect ENT's PROPEL(R) and SINUVA(R) sinus implants are clinically proven solutions that open sinus passageways and deliver an anti-inflammatory steroid to aid in healing. By combining these products with Medtronic's navigation, powered instruments, and existing tissue health products, the company intends to offer a broader suite of solutions to assist surgeons treating CRS patients.
Key features of the study
- This report provides an in-depth analysis of the global ENT disorder treatment market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global ENT disorder treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Sanofi, AstraZeneca, Novartis AG, Pfizer Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline Pharmaceuticals, Otonomy Inc., Merck & Co., Dr. Reddys Laboratories Ltd., Allergan plc, Cochlear Ltd., Sonova Holding AG, Siemens Healthcare, Starkey Laboratories Inc., William Demant Holding A/S, Widex A/S, GN ReSound A/S, Sonic Innovations Inc., Panasonic Corp., Beltone, Rexton Inc., Avada Hearing Care, Miracle-Ear Inc., MED-EL GmbH, Nuear Hearing Aids Inc., Audiosync Inc., Bernafon, American Hearing Systems Inc., Unitron Hearing Inc., and Zounds Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global ENT disorder treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ENT disorder treatment market
Market Segmentation
- Treatment Type Insights (Revenue, USD Bn, 2026 - 2033)
- By Devices
- Hearing Aid Devices
- Voice Prostheses
- Nasal Splints
- Hearing Implants
- Others
- By Drugs
- Antibiotics
- Antihistamines
- Steroids
- Anti-inflammatory Drugs
- Others
- Organ Type Insights (Revenue, USD Bn, 2026 - 2033)
- Ears
- Nose
- Throat
- End User Insights (Revenue, USD Bn, 2026 - 2033)
- Hospital
- Clinics
- Ambulatory Surgical Centers
- Home Care Settings
- Others
- Regional Insights (Revenue, USD Bn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
- Key Players Insights
- Sanofi
- AstraZeneca Plc
- Novartis AG
- Pfizer, Inc.
- Mylan N.V.
- Teva Pharmceutical Industries Ltd.
- GlaxoSmithKline Plc
- Otonomy, Inc.
- Merck & Co., Inc.
- Dr. Reddy's Laboratories Ltd.
- Allergen Plc
- Cochlear Ltd.
- Sonova Holdings AG.
- Siemens Healthineers
- Starkey Laboratories, Inc.
- William Demant Holdings, A/S
- Widex A/S
- GN Re/Sound A/S
- Sonic Innovations. Inc.
- Panasonic Corporation
- Beltone
- Rexton Inc.
- Avada Hearing Care
- Miracle-Ear., Inc.
- MED-EL GmBH
- Nuear Hearing Aids, Inc.
- AudioSync, Inc.
- Bernafon
- American Hearing Systems, Inc.
- Unitron Hearing, Inc.
- Zounds, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global ENT Disorder Treatment Market, By Treatment Type
- Global ENT Disorder Treatment Market, By Organ Type
- Global ENT Disorder Treatment Market, By End User
- Global ENT Disorder Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trend
4. Global ENT Disorder Treatment Market, By Treatment Type, 2020-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- By Devices
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Segment Trends
- Hearing Aid Devices
- Voice Prostheses
- Nasal Splints
- Hearing Implants
- Others
- By Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Segment Trends
- Antibiotics
- Antihistamines
- Steroids
- Anti-inflammatory Drugs
- Others
5. Global ENT Disorder Treatment Market, By Organ Type, 2020-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Ears
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Nose
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Throat
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
6. Global ENT Disorder Treatment Market, By End User, 2020-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Ambulatory Surgical Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Home Care Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Bn)
7. Global ENT Disorder Treatment Market, By Region, 2020 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Organ Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Organ Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Organ Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Organ Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Organ Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Treatment Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Organ Type, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca Plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan N.V.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline Plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Otonomy, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Dr. Reddy's Laboratories Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Allergen Plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cochlear Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sonova Holdings AG.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Siemens Healthineers
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Starkey Laboratories, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- William Demant Holdings, A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Widex A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GN Re/Sound A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sonic Innovations. Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Panasonic Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Beltone
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Rexton Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Avada Hearing Care
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Miracle-Ear., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- MED-EL GmBH
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Nuear Hearing Aids, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AudioSync, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bernafon
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- American Hearing Systems, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Unitron Hearing, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Zounds, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
